Quanta Therapeutics Inc. develops allosteric inhibitors for RAS-driven cancers. The company focuses on creating therapies targeting KRAS mutations.

Quanta Therapeutics Inc.

Novel therapeutics for conformational blockade of RAS in cancer.

Surveyor Capital

Vida Ventures

Logos Capital

AbbVie Biotech Ventures

Longitude Capital

Sofinnova Investments

BVF Partners

WS Investment Company

Avidity Partners

GC&H Investments

Biotechnology Value Fund

Quanta Therapeutics

Excited to share we’ve dosed our first patient in the Phase 1/1b clinical trial of QTX3046, an oral, dual (OFF/ON)-state KRASG12D-selective inhibitor and initiated patient dosing in the combination portion of the ongoing Phase 1 trial assessing QTX3034, a G12D-preferring multi-#KRAS inhibitor. Both are enrolling patients with KRASG12D-mutated advanced solid tumors. Learn more: https://bit.ly/4ciYUZ0

Looking forward to kicking off the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting with a trial in progress poster presentation on our Phase 1 clinical trial of QTX3034, an oral G12D-preferring multi-KRAS inhibitor. Hope to see you there!  Learn more: https://bit.ly/4dV2OZB #ASCO24 #KRAS

What an incredible honor to see Quanta’s CEO Perry Nisen, MD, PhD featured in the latest issue of Einstein Magazine in celebration of the 60th anniversary of the Albert Einstein College of Medicine’s Medical Scientist Training Program (MSTP). Congrats to Perry and all the MSTP physician-scientists who continue to play a critical role in advancing medicine. https://bit.ly/4aIbuQ6

Come join us at the 2024 American Society of Clinical Oncology (ASCO)  Annual Meeting for a poster presentation on the Phase 1 clinical trial of QTX3034, an oral G12D-preferring multi-KRAS inhibitor. Learn more here: https://bit.ly/4dV2OZB #ASCO24 #KRAS

We had a great time in San Diego this weekend at the American Association for Cancer Research Annual Meeting. Great to be a part of the building momentum of exciting and clinically significant developments from the cancer research community! Already looking forward to next year. #AACR24

Come join us as our Director of Preclinical Biology, Yang Zhang, presents our late-breaking presentation today at the American Association for Cancer Research Annual Meeting from 1:30 PM to 5:30 PM. #AACR24

#News: Excited to share that we’re highlighting research from our KRAS inhibitor pipeline in a late breaking poster at the American Association for Cancer Research Annual Meeting on Monday, April 8th at 1:30pm PT. We’ll be presenting data for QTX3544, a potent, selective, and orally bioavailable allosteric G12V-preferring multi-KRAS inhibitor, which demonstrated strong anti-tumor activity in preclinical models. Learn more: https://bit.ly/3J7Rs6a #KRAS #AACR24

Excited to be heading to the American Association for Cancer Research annual meeting today! Looking forward to some insightful presentations and important discussions on the latest #cancer research. There’s still time to join us, register here: bit.ly/3U2GHZa #AACR24 #KRAS

Thrilled to announce that we will be presenting at the American Association for Cancer Research (AACR) Annual Meeting. We hope you’ll join us on April 8th to hear more about the favorable preclinical properties of our G12V-preferring multi-KRAS inhibitor, QTX3544. Learn more here: https://bit.ly/48H69Yb

#News: Today we announced progress across our pipeline of KRAS-directed drug candidates, including IND clearance by the U.S. FDA for QTX3034, a G12D-preferring multi-KRAS inhibitor, enabling the initiation of a Phase 1 clinical trial in Q1 of 2024. Learn more here: https://bit.ly/48Hoip4 #KRASInhibitor

QUAN

COM:QUANTATX

Quanta Therapeutics Inc.

Filings Not Available